Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling

Glatiramer acetate during early pregnancy: A prospective cohort study

(2016) Sandra Herbstritt et al.   Multiple Sclerosis Journal

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

(2016) Sandra Thiel et al.   Multiple Sclerosis Journal

Glatiramer acetate during early pregnancy: A prospective cohort study

(2016) Sandra Herbstritt et al.   Multiple Sclerosis Journal

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

(2016) Sandra Thiel et al.   Multiple Sclerosis Journal

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany

(2016) Christine Poulos et al.   Therapeutic Advances in Neurological Disorders

Management of women with multiple sclerosis through pregnancy and after childbirth

(2016) Patricia K. Coyle   Therapeutic Advances in Neurological Disorders

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis

(2015) Clayton English et al.   CLINICAL THERAPEUTICS

Update on treatments in multiple sclerosis

(2015) Laure Michel et al.   PRESSE MEDICALE

Patient centered decision making: Use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices

(2014) Leslie Wilson et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Management of Multiple Sclerosis During Pregnancy and the Reproductive Years

(2014) Riley Bove et al.   OBSTETRICS AND GYNECOLOGY

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

(2014) Kathrin S. Utz et al.   Therapeutic Advances in Neurological Disorders

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance

(2013) Ellen Lu et al.   Expert Review of Neurotherapeutics

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod

(2013) Kristy Hanson et al.   Patient Preference and Adherence

Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis

(2013) Mickael Hiligsmann et al.   Patient Preference and Adherence

Shared Decision Making: A Model for Clinical Practice

(2012) Glyn Elwyn et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis

(2011) L. H. Visser et al.   EUROPEAN JOURNAL OF NEUROLOGY

Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

(2011) John F.P. Bridges et al.   VALUE IN HEALTH

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

(2010) Hiangkiat Tan et al.   ADVANCES IN THERAPY

Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy

(2009) F. Reed Johnson et al.   JOURNAL OF NEUROLOGY

Systematic Review of the Effects of Shared Decision-Making on Patient Satisfaction, Treatment Adherence and Health Status

(2008) E.A.G. Joosten et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS